There’s a New Doctor in Town, Kinda

The medical landscape in the United States is undergoing a seismic shift, driven by artificial intelligence and biotechnology. While giants like OpenAI and xAI grab headlines, a group of "hidden gems" is quietly solving the most frustrating bottlenecks in American healthcare.

Here is an overview of the key players defining the medical field in 2026 for The Letter.

The New Vanguard: Startups Redefining Medicine

The current era of innovation is characterized by "clinical-grade" technology—moving beyond simple apps to tools that fundamentally alter how diseases are diagnosed and treated.

  • Xaira Therapeutics: Launched with over $1 billion in funding, Xaira uses AI models to design novel proteins. They target "undruggable" diseases, using AI to build custom biological keys for locks previously considered impossible to open.
  • eGenesis: Addressing the chronic shortage of donor organs, this startup is pioneering xenotransplantation. By using CRISPR to genetically engineer pig organs, they are moving us closer to a future where organ waiting lists are a thing of the past.
  • Abridge: This "Ambient AI" leader is tackling physician burnout. Its system listens to patient-doctor conversations in real-time and automatically drafts structured clinical notes, saving doctors up to 75% of their documentation time.

  • Expert Insight
  • "The most successful startups of 2026 are those that respect the 'last mile' of healthcare. It’s no longer enough to have a great algorithm; you have to solve for the friction of the doctor’s workflow and the reality of the patient’s daily life. The 'hidden gems' are those making innovation invisible."
  • Dr. Marc Tessier-Lavigne, CEO of Xaira Therapeutics and former President of Stanford University.

The Hidden Gems: Under-the-Radar Innovators

Beyond the billion-dollar valuations, these companies are making innovation "invisible" by integrating directly into the daily lives of patients and clinicians.

  • Soundable Health: This startup uses AI-powered acoustic analysis to enable clinical-grade diagnostics through smartphones. Its FDA-cleared solution, proudP, analyzes the sound of urine flow to track prostate and bladder health at home with 97% accuracy.
  • EnsoData: Turning bedrooms into diagnostic labs, EnsoData uses AI to analyze data from existing wearables and bedside monitors to provide clinical-grade sleep diagnostics, bypassing the need for expensive hospital sleep suites.
  • Hippocratic AI: While many focus on notes, Hippocratic is building "safety-first" LLMs specifically for healthcare. Their AI agents handle non-diagnostic tasks like pre-op instructions and post-discharge follow-ups, acting as a scalable extension of the nursing staff.
  • Reperio Health: Revolutionizing preventative care, Reperio provides at-home health screening kits that measure blood pressure, glucose, and cholesterol with instant cloud-syncing for physician review.

Latest News

image
The Rise of the AI Specialist
by Ken Hubbard | 2026-03-31
image
What to Prepare for in the Market This Week
by Ken Hubbard | 2026-03-24
image
When Moderation Beats Reflex
by Ken Hubbard | 2026-03-20
image
The Strait Is Loud, but the World Is Working
by Ken Hubbard | 2026-03-19

Highlights

Read Next

There’s a New Doctor in Town, Kinda
by Ken Hubbard | 2026-04-01
image
The Rise of the AI Specialist
by Ken Hubbard | 2026-03-31
image

Get The Letter

More from Business


image
The medical landscape in the United States is undergoing a seismic shift
by Ken Hubbard | 2026-04-01
image
The Death of the “Generalist” (And the Rise of the AI Specialist)
by Ken Hubbard | 2026-03-31
image
With the Dow and Nasdaq entering technical correction territory
by Ken Hubbard | 2026-03-30
image
Investing in vintage cars can feel like stepping into a world of chrome, nostalgia, and roaring engines—but beneath the beauty lies a market that can be just as volatile as stocks.
by Christian Morano | 2026-03-27
image
The world of investing often feels dominated by a select few names: Apple, Amazon, Tesla, and the ubiquitous S&P 500.
by Ken Hubbard | 2026-03-25
image
Trying to predict the market week-to-week is a losing game.
by Ken Hubbard | 2026-03-24
© 2026 The Letter. All rights reserved, Privacy Policy